Synergistic antibacterial activity of medium polarity oils in combination with antibacterial agents on bacterial biofilms
The compositions of the present invention comprise at least one medium polarity oil and at least one antibacterial agent, the combination of which produces a synergistic antibacterial effect against bacterial biofilms. Methods are disclosed for the reduction of bacteria in and/or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms.
1. A method of treating a wound, mucous membrane lesion, or skin lesion infected or contaminated with a bacterial biofilm, the method comprising topically administering to the wound, mucous membrane lesion, or skin lesion a composition consisting essentially of a pharmaceutical carrier and a sole anti-bacterial agent, wherein the anti-bacterial agent consists of a combination of a medium polarity oil having an octanol-water partition coefficient (log P) of 0.5 to 2.0 and at least one silver compound, wherein the medium polarity oil is benzyl alcohol or propyl gallate and is at a concentration of 4.5% w/w to 5.5% w/w, wherein the silver compound is at a concentration of 0.5% w/w to 1.5% w/w, and wherein the combination consisting of the medium polarity oil and the silver compound produces a synergistic antibacterial effect against bacteria in the biofilm.
2. The method of claim 1 , wherein the silver compound is silver nitrate, silver sulfadiazine, or silver chloride.
3. The method of claim 1 , wherein the silver compound is silver nitrate.
4. The method of claim 1 , wherein the pharmaceutical carrier is a lotion, solution, suspension, liquid, emulsion, cream, gel, ringing gel, ointment, paste, aerosol spray, aerosol foam, non-aerosol spray, non-aerosol foam, film, or sheet.
5. The method of claim 1 , wherein the bacterial biofilm is a gram-positive bacterial biofilm.
6. The method of claim 5 , wherein the gram-positive bacterium is Staphylococcus aureus or methicillin resistant Staphylococcus aureus (MRSA).
7. The method of claim 1 , wherein the wound is a chronic wound.
8. The method of claim 7 , wherein the chronic wound is a diabetic foot ulcer, venous ulcer, arterial ulcer, decubitus ulcer, stasis ulcer, pressure ulcer, or burn.
9. The method of claim 1 , wherein the mucous membrane lesion or skin lesion is a blister, ulceration, abrasion, wart, scrape, or infection.